Table 2.
sCD30, sCD26 (DPPIV) enzyme activity and CMV antigen-induced lymphoproliferation and IFN-γ responses in controls and patient groups
| Current plasma HIV RNA (× 103 copies/ml) | n | CD4+ T cells/µl | sCD30 (u/ml) | CD26 (DPPIV) enzyme activity (u/ml) | |
|---|---|---|---|---|---|
| Controls | 25 | N/A | 123 (11–780)* | 221 (136–572) | |
| Group 1 | 31 | 280 (60–1107) | 143 (20–7097) | 259 (125–1344) | |
| > 0·4 | 13 | 182 (60–392)† | 183 (60–7097)† | 400 (168–1344)† | |
| < 0·4 | 18 | 355 (60–1107) | 69 (30–2646) | 250 (153–696) | |
| Group 2 | 10 | 11 (2–45) | 84 (27–3527) | 212 (89–712) |
| Proliferation (DPM × 10−3) | IFN-γ in cell culture supernatants (U/ml) | IFN-γ ELISpot (per 2 × 105 cells) | |||
|---|---|---|---|---|---|
| Controls | 12 | 59(4–212) | 2·1 (0·2–38) | 80 (14–400) | |
| Group 1 | 29 | 5 (0·2–118)‡ | 0·4 (0·1–15)‡ | 33 (0–315) | |
| Group 2 | 7 | 0·8 (0·3–1·4)‡ | 0·2 (0·1–4)‡ | 1 (0–3)‡ |
*
Median (range).
†
Significantly different from Group 1 patients with < 400 copies HIV RNA/ml (P = 0·01 for CD4 + T-cell counts, P = 0·03 for CD26 (DPPIV) enzymeactivity and P = 0·003 for sCD30).
†
Significantly different from control subjects (P < 0·05).